药品注册申请号:018487
申请类型:NDA (新药申请)
申请人:MYLAN
申请人全名:MYLAN PHARMACEUTICALS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG No No AB 1981/08/27 Approved Prior to Jan 1, 1982 Discontinued
002 FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG No No AB Approved Prior to Jan 1, 1982 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2016/03/08 SUPPL-43(补充) Approval Labeling STANDARD
2010/02/12 SUPPL-40(补充) Approval Manufacturing (CMC)
2008/11/04 SUPPL-38(补充) Approval Labeling
2001/09/25 SUPPL-32(补充) Approval Manufacturing (CMC)
2001/09/25 SUPPL-31(补充) Approval Manufacturing (CMC)
1998/12/07 SUPPL-30(补充) Approval Manufacturing (CMC)
1998/02/25 SUPPL-29(补充) Approval Manufacturing (CMC)
1998/02/05 SUPPL-28(补充) Approval Manufacturing (CMC)
1997/10/06 SUPPL-27(补充) Approval Labeling
1996/04/29 SUPPL-26(补充) Approval Labeling
1994/01/07 SUPPL-25(补充) Approval Manufacturing (CMC)
1993/06/15 SUPPL-24(补充) Approval Labeling
1993/04/13 SUPPL-22(补充) Approval Labeling
1992/05/06 SUPPL-21(补充) Approval Labeling
1992/03/18 SUPPL-20(补充) Approval Labeling
1990/12/27 SUPPL-19(补充) Approval Labeling
1990/07/05 SUPPL-18(补充) Approval Labeling
1989/10/13 SUPPL-13(补充) Approval Labeling
1989/09/19 SUPPL-16(补充) Approval Manufacturing (CMC)
1988/03/01 SUPPL-15(补充) Approval Manufacturing (CMC)
1988/03/01 SUPPL-14(补充) Approval Manufacturing (CMC)
1985/01/09 SUPPL-7(补充) Approval Manufacturing (CMC)
1981/08/27 ORIG-1(原始申请) Approval
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:FUROSEMIDE 剂型/给药途径:TABLET;ORAL 规格:20MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
016273 002 NDA LASIX FUROSEMIDE TABLET;ORAL 20MG Prescription Yes No AB Approved Prior to Jan 1, 1982 VALIDUS PHARMS
018487 001 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Discontinued No No AB Approved Prior to Jan 1, 1982 MYLAN
018569 002 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB Approved Prior to Jan 1, 1982 EPIC PHARMA LLC
018823 001 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB 1983/11/10 HIKMA
076796 001 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB 2004/03/26 PRINSTON INC
077293 001 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB 2005/11/09 LEADING
078010 001 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB 2006/09/18 IPCA LABS LTD
216629 001 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 20MG Prescription No No AB 2022/10/17 GRAVITI PHARMS
活性成分:FUROSEMIDE 剂型/给药途径:TABLET;ORAL 规格:40MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
016273 001 NDA LASIX FUROSEMIDE TABLET;ORAL 40MG Prescription Yes No AB Approved Prior to Jan 1, 1982 VALIDUS PHARMS
018487 002 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Discontinued No No AB Approved Prior to Jan 1, 1982 MYLAN
018569 001 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB Approved Prior to Jan 1, 1982 EPIC PHARMA LLC
018823 002 NDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB 1983/11/10 HIKMA
076796 002 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB 2004/03/26 PRINSTON INC
077293 002 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB 2005/11/09 LEADING
078010 002 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB 2006/09/18 IPCA LABS LTD
216629 002 ANDA FUROSEMIDE FUROSEMIDE TABLET;ORAL 40MG Prescription No No AB 2022/10/17 GRAVITI PHARMS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database